Anna Nowak-Wegrzyn1, Alessandro Fiocchi. 1. Jaffe Food Allergy Institute and Department of Pediatrics, Mount Sinai School of Medicine, New York, NY 10029, USA. anna.nowak-wegrzyn@mssm.edu
Abstract
PURPOSE OF REVIEW: To review current evidence on food oral immunotherapy (OIT). RECENT FINDINGS: Desensitized state, defined as the ingestion of a substantial amount of food in the home diet that protects from severe reactions to accidental exposures, can be achieved by approximately 50-75% of the children treated with OIT. The rate of permanent tolerance is unknown; the longer duration of OIT may result in permanent tolerance. Side effects are common both during the initial dose escalation and during home dosing. Most reactions are mild (oral pruritus, abdominal discomfort, and rashes) and decrease in frequency with the longer duration of OIT. Severe reactions treated with epinephrine have been reported during home dosing. Factors associated with increased risk of reactions to previously tolerated doses during home dosing include exercise, viral infection, dosing on empty stomach, menses, and asthma exacerbation. SUMMARY: These preliminary data on OIT are encouraging. Additional studies must answer multiple questions including optimal dose, ideal duration of oral/sublingual immunotherapy, degree of protection, efficacy for different ages, severity and type of food allergy responsive to treatment and need for patient protection during home administration. Until these questions are answered in rigorous multicenter randomized and placebo-controlled trials, OIT remains an experimental approach with not sufficiently well established risk-to-benefit ratio.
PURPOSE OF REVIEW: To review current evidence on food oral immunotherapy (OIT). RECENT FINDINGS: Desensitized state, defined as the ingestion of a substantial amount of food in the home diet that protects from severe reactions to accidental exposures, can be achieved by approximately 50-75% of the children treated with OIT. The rate of permanent tolerance is unknown; the longer duration of OIT may result in permanent tolerance. Side effects are common both during the initial dose escalation and during home dosing. Most reactions are mild (oral pruritus, abdominal discomfort, and rashes) and decrease in frequency with the longer duration of OIT. Severe reactions treated with epinephrine have been reported during home dosing. Factors associated with increased risk of reactions to previously tolerated doses during home dosing include exercise, viral infection, dosing on empty stomach, menses, and asthma exacerbation. SUMMARY: These preliminary data on OIT are encouraging. Additional studies must answer multiple questions including optimal dose, ideal duration of oral/sublingual immunotherapy, degree of protection, efficacy for different ages, severity and type of food allergy responsive to treatment and need for patient protection during home administration. Until these questions are answered in rigorous multicenter randomized and placebo-controlled trials, OIT remains an experimental approach with not sufficiently well established risk-to-benefit ratio.
Authors: N V Batista; R V S Pereira; M L M Noviello; L P A Dourado; D A Perez; G Foureaux; A J Ferreira; A V M Ferreira; D C Cara Journal: Clin Exp Immunol Date: 2014-12 Impact factor: 4.330
Authors: Montserrat Alvaro; Ma Teresa Giner; Marta Vázquez; Jaime Lozano; Olga Domínguez; Mónica Piquer; Marcia Días; Rosa Jiménez; Ma Anunciación Martín; Laia Alsina; Ana Ma Plaza Journal: Eur J Pediatr Date: 2012-05-11 Impact factor: 3.183
Authors: Carina Venter; Trevor Brown; Rosan Meyer; Joanne Walsh; Neil Shah; Anna Nowak-Węgrzyn; Tong-Xin Chen; David M Fleischer; Ralf G Heine; Michael Levin; Mario C Vieira; Adam T Fox Journal: Clin Transl Allergy Date: 2017-08-23 Impact factor: 5.871